HeartBeam has secured two new US patents, strengthening its intellectual property (IP) portfolio in cardiac monitoring technology.
The first patent pertains to the company鈥檚 cable-free three-dimensional (3D) electrocardiogram (ECG) device, which is roughly the size of a credit card.
The device has been tailored for convenience, incorporating chest and finger electrodes to capture high-fidelity electrical signals from three non-coplanar directions.
Individuals can use the device to record symptoms as they occur, regardless of their location.
The captured signals are synthesised into a 12-lead ECG through a personalised transformational matrix.
HeartBeam’s 12-lead ECG synthesis software is undergoing US Food and Drug Administration (FDA) review.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe VALID-ECG pivotal study, which assessed the ECG in non-life-threatening arrhythmias, confirmed that the device met its clinical endpoints.
The second patent secures the company鈥檚 rhythm analysis algorithm, which can identify arrhythmias such as atrial fibrillation and sinus rhythm from continuous signal input.
It can be integrated into any cardiac monitoring system, including wearables, and facilitates risk-based escalation by identifying anomalies during passive monitoring.
The algorithm can prompt users to gather 3D ECG signals with the company鈥檚 device for a 12-lead ECG.
The company’s portfolio now includes 20 issued patents across the US and internationally, two allowed and 32 pending patents.
HeartBeam CEO Robert Eno stated: 鈥淗eartBeam鈥檚 vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility.
鈥淭he new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.鈥�
HeartBeam recently entered a partnership with AccurKardia, a company specialising in ECG-based diagnostics software, to enhance the accessibility of cardiac monitoring solutions.
In December 2024, HeartBeam’s 3D ECG technology was granted FDA clearance for arrhythmia assessment.
